Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Bridging Study of CVT-301 vs Sinemet
NCT02812394Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levodopa in Parkinson's disease (PD) (3 arms), sponsored by Acorda Therapeutics. Primary endpoints: Maximum observed plasma drug concentration and Area under the plasma concentration curve from time 0 to 24 hours. Started Jun 2016; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02812394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812394.